OBJECTIVE: Pacing technology and care have improved notably over the past decade, justifying an update on the long-term prognosis and pre-implantation determinants of prognosis of bradycardia pacemaker (PM) recipients. DESIGN: Prospective cohort study. SETTING: 23 Dutch pacemaker centres PATIENTS: Pre-implantation characteristics of 1517 patients receiving a first bradycardia PM between 2003-2007 were studied in relation to survival. INTERVENTIONS: None; patients were followed up during routine clinical practice. MAIN OUTCOME MEASURES: Cause and time to death. RESULTS: At the end of a mean follow-up of 5.8 (SD 1.1) years, 512 patients (33%) died, mostly of non-cardiac cause (67%). There were two PM related deaths. Survival rates were 93%, 81%, 69%, and 61% after 1, 3, 5 and 7 years, respectively. PM recipients without concomitant cardiovascular disease at implantation showed survival rates comparable to age and sex matched controls. Predictors at time of implantation associated with cardiac mortality were: age, coronary artery disease (CAD), diabetes, heart failure, valve disease, and the indication for PM implantation. Predictors for all cause mortality were: male gender, age, body mass index, CAD, cardiac surgery, diabetes, heart failure, and maintained atrioventricular synchrony. CONCLUSIONS: A pre-implantation history of heart failure, CAD, and diabetes are the most important predictors for worse prognosis in PM recipients. Without baseline heart disease, survival rates equal that of the general population, suggesting that the prognosis of contemporary PM recipients is mainly determined by comorbid diseases and a bradycardia pacing indication as such does not influence survival. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00135174.
OBJECTIVE: Pacing technology and care have improved notably over the past decade, justifying an update on the long-term prognosis and pre-implantation determinants of prognosis of bradycardia pacemaker (PM) recipients. DESIGN: Prospective cohort study. SETTING: 23 Dutch pacemaker centres PATIENTS: Pre-implantation characteristics of 1517 patients receiving a first bradycardia PM between 2003-2007 were studied in relation to survival. INTERVENTIONS: None; patients were followed up during routine clinical practice. MAIN OUTCOME MEASURES: Cause and time to death. RESULTS: At the end of a mean follow-up of 5.8 (SD 1.1) years, 512 patients (33%) died, mostly of non-cardiac cause (67%). There were two PM related deaths. Survival rates were 93%, 81%, 69%, and 61% after 1, 3, 5 and 7 years, respectively. PM recipients without concomitant cardiovascular disease at implantation showed survival rates comparable to age and sex matched controls. Predictors at time of implantation associated with cardiac mortality were: age, coronary artery disease (CAD), diabetes, heart failure, valve disease, and the indication for PM implantation. Predictors for all cause mortality were: male gender, age, body mass index, CAD, cardiac surgery, diabetes, heart failure, and maintained atrioventricular synchrony. CONCLUSIONS: A pre-implantation history of heart failure, CAD, and diabetes are the most important predictors for worse prognosis in PM recipients. Without baseline heart disease, survival rates equal that of the general population, suggesting that the prognosis of contemporary PM recipients is mainly determined by comorbid diseases and a bradycardia pacing indication as such does not influence survival. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00135174.
Authors: Emelia J Benjamin; Michael J Blaha; Stephanie E Chiuve; Mary Cushman; Sandeep R Das; Rajat Deo; Sarah D de Ferranti; James Floyd; Myriam Fornage; Cathleen Gillespie; Carmen R Isasi; Monik C Jiménez; Lori Chaffin Jordan; Suzanne E Judd; Daniel Lackland; Judith H Lichtman; Lynda Lisabeth; Simin Liu; Chris T Longenecker; Rachel H Mackey; Kunihiro Matsushita; Dariush Mozaffarian; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Latha Palaniappan; Dilip K Pandey; Ravi R Thiagarajan; Mathew J Reeves; Matthew Ritchey; Carlos J Rodriguez; Gregory A Roth; Wayne D Rosamond; Comilla Sasson; Amytis Towfighi; Connie W Tsao; Melanie B Turner; Salim S Virani; Jenifer H Voeks; Joshua Z Willey; John T Wilkins; Jason Hy Wu; Heather M Alger; Sally S Wong; Paul Muntner Journal: Circulation Date: 2017-01-25 Impact factor: 29.690
Authors: Maciej Dębski; Mateusz Ulman; Andrzej Ząbek; Krzysztof Boczar; Kazimierz Haberka; Marcin Kuniewicz; Jacek Lelakowski; Barbara Małecka Journal: Cardiol J Date: 2018-08-29 Impact factor: 2.737
Authors: Tanwier T T K Ramdjan; Lisette J M E van der Does; Paul Knops; Jan C J Res; Natasja M S de Groot Journal: Trials Date: 2014-11-17 Impact factor: 2.279
Authors: Johnni Rudbeck-Resdal; Morten K Christiansen; Jens B Johansen; Jens C Nielsen; Henning Bundgaard; Henrik K Jensen Journal: Europace Date: 2019-11-01 Impact factor: 5.214
Authors: Martin Riesenhuber; Andreas Spannbauer; Friedrich Rauscha; Herwig Schmidinger; Adelinde Boszotta; Thomas Pezawas; Christoph Schukro; Marianne Gwechenberger; Günter Stix; Anahit Anvari; Thomas Wrba; Cesar Khazen; Martin Andreas; Günther Laufer; Christian Hengstenberg; Mariann Gyöngyösi Journal: Front Cardiovasc Med Date: 2020-09-22